-
With results just published for a Phase I clinical trial and data for a Phase I/II trial in analysis, developers of what is being dubbed the Invisible Condom are looking toward initiation of a Phase III randomized controlled trial to test the safety and efficacy of the potential microbicide.
-
Tick off the contraceptive options now available at your clinic. If you are a provider at a university health center, chances are your list may be shorter than it was in 2007.
-
Over-the-counter contraceptive products that contain the spermicide nonoxynol-9 (N-9) now will carry a warning label to alert consumers that such products do not protect against sexually transmitted diseases (STDs) and HIV/AIDS, following a final ruling by the Food and Drug Administration (FDA).
-
It's time to redouble efforts to stem adolescent pregnancy. Preliminary birth statistics released by the Centers for Disease Control and Prevention indicate the U.S. birth rate rose by 3% between 2005 and 2006 among females 15-19 after dropping 34% between 1991 and 2005.
-
What is your level of knowledge when it comes to genital herpes, its methods of virus transmission, risks to others, and appropriate treatment? If results of an online survey are any indication, many health care providers and patients with herpes are poorly informed about herpes.
-
While you may be comfortable with menstrual suppression through use of continuous oral contraceptives (OCs), are your patients? According to results from a national survey, more than 66% of women say that they are interested in suppressing their menstrual periods, but many of them aren't sure if it's safe.
-
New research indicates that a rapid test that uses self-collected vaginal swabs may be effective in diagnosing chlamydia.1 With its ability to deliver results in less than 30 minutes, the test, now in development, would give clinicians a same-day diagnostic and screening tool for chlamydial infection.
-
Review the number of sexually transmitted diseases (STDs) detected in your patient population over the last year.
-
Could a new combined oral contraceptive (OC) be available to U.S. women? Organon is conducting two Phase 3a trials for the first monophasic oral contraceptive containing estradiol (E2) and a new progestin, nomegestrol acetate (NOMAC).
-
Good news for your older female patients: Calcium, or calcium in combination with vitamin D, may prevent osteoporosis in those age 50 and older, results from a new meta-analysis show.